Update in systemic therapy of prostate cancer: improvement in quality and duration of life.
about
Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.Targeted drug and gene delivery systems for lung cancer therapy.Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
P2860
Update in systemic therapy of prostate cancer: improvement in quality and duration of life.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Update in systemic therapy of ...... quality and duration of life.
@en
Update in systemic therapy of ...... quality and duration of life.
@nl
type
label
Update in systemic therapy of ...... quality and duration of life.
@en
Update in systemic therapy of ...... quality and duration of life.
@nl
prefLabel
Update in systemic therapy of ...... quality and duration of life.
@en
Update in systemic therapy of ...... quality and duration of life.
@nl
P2860
P356
P1476
Update in systemic therapy of ...... quality and duration of life.
@en
P2093
Maha Hussain
Ulka Vaishampayan
P2860
P304
P356
10.1586/14737140.8.2.269
P577
2008-02-01T00:00:00Z